Abstract. Renal-type clear cell carcinoma of the prostate is a rare and novel tumor that has only been identified in recent years. The present study describes a lesion in the prostate of a 64-year-old male with a two-year history of urinary frequency, urgency and difficulty, who was admitted to the San Ai Tang Hospital for benign prostatic hyperplasia, and subsequently underwent transurethral resection of the prostate. In total, 12 g of tissue was resected, which demonstrated morphological and immunohistochemical similarities to clear cell carcinoma of the kidney. Ultrasound inspection and computed tomography revealed prostate enlargement. Although no renal-enclosed mass was identified, metastatic lesions were revealed in the lungs, sternum and clavicles. In addition, right pleural thickening and a small amount of effusion in the pleural cavity were detected. Clear cell carcinoma was identified throughout the prostate, with surrounding regions of ordinary-type prostatic adenocarcinoma (Gleason score, 4+4). The urinary bladder exhibited no dysplasia or neoplasia. It was therefore concluded that the tumor represented a primary renal-type clear cell carcinoma that had arisen in the prostate. To the best of our knowledge, this type of extra-renal tumor has only been reported in three other previous studies. IntroductionClear cell carcinomas that occur in the lower urinary tract are usually variants of more frequently diagnosed cancers, including prostatic adenocarcinoma and transitional cell carcinoma (1), however, they may also be a less common type of carcinoma, such as clear cell carcinoma, which is similar to Müllerian tumors and metastatic renal cell carcinomas (RCCs) (2). RCC is the most common subtype of clear cell carcinoma, which originates from renal tubular epithelial cells and accounts for 85% of all renal tumors (3). Patients with RCC are usually asymptomatic in the early stages of the disease, however, as the tumor size increases patients most commonly present with a lump in the lower abdomen or back, lower back pain and hematuria (4). The most common sites of RCC metastases are the lungs, bone and liver (5,6). However, metastases affecting the lower urinary tract, namely the prostate and bladder, are extremely rare (7,8). In 2012, the worldwide age-standardized mortality rate for RCC was 1.8 deaths per 100,000 individuals (9). At present, treatment for RCC includes radical surgery, immunotherapy and chemotherapy (10). To the best of our knowledge, renal-type clear cell carcinoma occurring as a primary tumor in an extra-renal location has only been described in three other previous studies (11-13) which revealed that RCC of the prostate is a novel pathological entity, that exhibits histological and immunhistochemical features similar to those of RCC. Case reportA 64-year-old male with a two-year history of urinary frequency, urgency and difficulty, that had undergone treatment with a detaining urethral catheter for eight days, was referred to the San Ai Tang Hospital (Lanzhou, China) due to lower urina...

Background: To assess the effects of single polycyclic aromatic hydrocarbons (PAHs) on solid tumor initiation, and investigate their roles in immune response regulation. Material/Methods: Mice (100) were randomly divided into 5 groups (n=20) to be intraperitoneally injected with 10 daily doses of DMSO (control), anthracene (50 mg/kg), benzo-(a)-pyrene (10 mg/kg), benzo-(a)-pyrene (20 mg/kg), and benzo-[G, H, I])-perylene (5 mg/kg), respectively. Three months later, serum IL-2 and IL-6 levels were assessed by ELISA; liver, kidney, stomach and lung tissues were subjected to histopathological examinations. Results: Liver cancer incidences after benzo-[G, H, I]-perylene, benzo-(a)-pyrene (10 mg/kg), benzo-(a)-pyrene (20 mg/kg), and anthracene were 21.1, 26.3, 35.3, and 27.8%, respectively; 21.1, 0, 41.2, and 0% showed stomach cancer, respectively; 0, 0, 11.8 and 0% displayed kidney cancer, respectively. The occurrences of precancerous liver lesions for benzo-[G, H, I]-perylene, benzo-(a)-pyrene (10 mg/kg), benzo-(a)-pyrene (20 mg/kg) and anthracene groups, respectively, were 68.4, 73.7, 64.7, and 55.6%; 78.9, 68.4, 29.4, and 27.8% showed precancerous stomach lesions, while 42.1, 47.4, 58.8, and 33.3% had precancerous kidney lesions; respectively. No obvious lung lesions were found in any group. Serum IL-2 and IL-6 levels in treatment groups were significantly lower compared with control values (P<0.01). Conclusions: PAHs induce cancer and precancerous lesions in the liver, stomach, and kidney. Benzo (a) pyrene initiates gastric cancer in a dose-dependent manner, but does not induce precancerous lung lesions. Lower IL-2 and IL-6 levels in treatment groups compared with controls suggest that PAHs cause overt immune inhibition.

Background:Surgical resection is the recommended procedure for colorectal cancer (CRC), but majority of the patients were diagnosed with advanced or metastatic CRC. Currently, there were inconsistent results about the diagnostic value of magnetic resonance colonography (MRC) and computed tomography colonography (CTC) in early CRC diagnosis. Our study conducted this meta-analysis to investigate the diagnostic value of MRC and CTC for CRC surveillance.Methods:A comprehensive literature search was conducted in PubMed, Embase, and the Cochrane library to select relevant studies. The summary sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and the area under the receiver operating characteristic curves (AUC) were calculated to evaluate the diagnostic value of MRC and CTC, respectively.Result:Twenty-five studies including 2985 individuals were selected in the final analysis. Eight studies evaluated the diagnostic value of MRC, and 17 studies assessed CTC. The summary sensitivity, specificity, PLR, NLR, DOR, and AUC in MRC for early detection of CRC were 0.98 (95% confidence interval, CI: 0.80–1.00), 0.94 (95% CI: 0.85–0.97), 15.48 (95% CI: 6.30–38.04), 0.02 (95% CI: 0.00–0.25), 115.09 (95% CI: 15.37–862.01), and 0.98 (95% CI: 0.97–0.99), respectively. In addition, the sensitivity, specificity, PLR, NLR, DOR, and AUC of CTC for diagnosing CRC were 0.97 (95% CI: 0.88–0.99), 0.99 (95% CI: 0.99–1.00), 154.11 (95% CI: 67.81–350.22), 0.03 (95% CI: 0.01–0.13), 642.51 (95% CI: 145.05–2846.02), and 1.00 (95% CI: 0.99–1.00). No significant differences were found between MRC and CTC for DOR in all the subsets.Conclusion:The findings of meta-analysis indicated that MRC and CTC have higher diagnostic values for early CRC diagnosis. However, the DOR for diagnosing CRC between MRC and CTC showed no significance.